China Top Purity >99% Main Estrogens CAS 50-27-1 Estriol in Treating Multiple Sclerosis, Find details about China Estriol, CAS 50-27-1 from Top Purity >99% Main Estrogens CAS 50-27-1 Estriol in Treating Multiple Sclerosis
Product Description
Estriol
CAS No.: 50-27-1
Molecular Weight: 288.3814
Molecular Formula: C18H24O3
Appearance: White crystalline powder
Specification:USP
MOQ: 10g
Grade: Pharmaceutical Grade
Storage: Shading, confined preservation.
Description of Estriol :
1. Estriol can be a weak or strong estrogen depending on if it is given acutely or chronically when given to immature animals, but is an antagonist when given in combination with estradiol.
2. Estriol may play a role in the development of breast cancer, but based on in vitro research, does appear to act as an antagonist to the G-protein coupled estrogen receptor. Though estriol is used as part of the primarily North American phenomenon of bioidentical hormone replacement therapy, it is not approved for use by the FDA or Health Canada.Though initial research in the 1970s suggested it could be used therapeutically as an estrogen,subsequent research failed to confirm this hypothesis.In pregnant women with multiple sclerosis, estriol reduces the disease's symptoms noticeably, according to researchers at UCLA's Geffen Medical School.
3. Estriol can be a weak or strong estrogen depending on if it is given acutely or chronically when given to immature animals, but is an antagonist when given in combination with estradiol.
4. Estriol may play a role in the development of breast cancer, but based on in vitro research, does appear to act as an antagonist to the G-protein coupled estrogen receptor. Though estriol is used as part of the primarily North American phenomenon of bioidentical hormone replacement therapy, it is not
approved for use by the FDA or Health Canada.
COA :
ITEM | SPECIFICATION | RESULT |
Character | White or almost white crystalline powder | White crystalline powder |
Specific rotation | +54°to +62° | +59.9° |
Completeness of solution | Clear and free from undissolved solid | Conforms |
Identification | (1) complies by IR (2) complies by UV | Conforms Conforms |
Residue on Ignition | Not more than 0.1% | 0.05% |
Loss on drying | Not more than 0.5 | 0.1% |
Chromatographic purity | Total impurities not more than 2.0% | <2.0% |
Assay | It should contain 97.0% to 102.0% of C18H24O3 calculated on dried basis | 98.4% |
Particle size | It should be 90% below 30μm | Conforms |
Conclusion | Conforms to USP36 |
Other SARMs
Name | CAS NO. | Usage |
AICAR | 2627-69-2 | acts by entering nucleoside pools, significantly increasing levels of adenosine during periods of ATP breakdown |
MK2866 | 841205-47-8 | medical prescription for prevention of cachexia, atrophy, and sarcopenia and for Hormone or Testoserone Replacement Therapy. |
MK-677 | 15972-10-0 | for the treatment of frailty in the elderly |
LGD-4033 | 1165910-22-4 | pharmacological profile similar to that of enobosarm, Ostarine,MK-2866 |
GW1516 | 317318-70-0 | For obesity, diabetes, dyslipidemia and cardiovascular disease |
Andarine(S4) | 401900-40-0 | partial agonist, intended mainly for treatment of benign prostatic hypertrophy |
SR9009 | 1379686-30-2 | under development at The Scripps Research Institute (TSRI), increases the level of metabolic activity in skeletal muscles of mice |
RAD140 | 1182367-47-0 | New generation for gaining mass and cutting edges |
YK11 | 431579-34-9 | YK11: a SARM and myostatin inhibitor in one |
AC262356 | 870888-46-3 | New SARMS |
SR9011 | 1379686-29-9 | New SARMS |
S23 | 1010396-29-8 | New SARMS |
GW0724 | 317318-84-6 | New SARMS |